{"organizations": [], "uuid": "edd098875825594ad963af5ef73b2760ffeeb04c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/fresenius-results/fresenius-q1-net-income-slips-2-pct-on-strong-euro-idUSS8N1LG00K", "country": "US", "domain_rank": 408, "title": "Fresenius Q1 net income slips 2 pct on strong euro", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-03T13:14:00.000+03:00", "replies_count": 0, "uuid": "edd098875825594ad963af5ef73b2760ffeeb04c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/fresenius-results/fresenius-q1-net-income-slips-2-pct-on-strong-euro-idUSS8N1LG00K", "ord_in_thread": 0, "title": "Fresenius Q1 net income slips 2 pct on strong euro", "locations": [], "entities": {"persons": [{"name": "edward taylor our", "sentiment": "none"}, {"name": "caroline copley", "sentiment": "none"}, {"name": "stephan sturm", "sentiment": "none"}], "locations": [{"name": "berlin", "sentiment": "none"}, {"name": "north america", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "fresenius se", "sentiment": "negative"}, {"name": "fresenius", "sentiment": "negative"}, {"name": "ludwig burger editing", "sentiment": "none"}, {"name": "akorn", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BERLIN, May 3 (Reuters) - German healthcare group Fresenius SE posted a slight decline in quarterly profit on Thursday, hurt by a strong euro, and confirmed its full-year guidance.\nFirst-quarter net income slipped 2 percent to 450 million euros ($539 million), which surpassed the 437 million consensus forecast in a Reuters poll.\nSales in the January-to-March period edged 1 percent lower to 8.12 billion euros, broadly in line with the analysts’ consensus forecast.\nFresenius is bracing for a legal battle with Akorn after pulling out of its planned $4.7 billion takeover.\nChief Executive Stephan Sturm reiterated that the company would look for alternative ways to grow.\n“We will continue to pursue the strategic goal of expanding our portfolio of injectable generic drugs in North America,” he said.\n$1 = 0.8343 euros Reporting by Caroline Copley and Ludwig Burger Editing by Edward Taylor\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-03T13:14:00.000+03:00", "crawled": "2018-05-04T17:23:08.004+03:00", "highlightTitle": ""}